AASLD 2010
Add-on Adefovir Is More Effective and Durable Than Switch to Entecavir as Rescue Therapy
- Details
- Category: HBV Treatment
- Published on Tuesday, 09 November 2010 12:48
- Written by Liz Highleyman
Adding adefovir (Hepsera) is more effective and durable than switching to entecavir (Baraclude) as rescue therapy for Epivir-resistant patients with chronic hepatitis B, according to a study presented in Boston last week at AASLD 2010. The mean reduction of serum HBV DNA levels was significantly less in the entecavir group than in the add-on adefovir group at weeks 24 and 48. In addition, the rate of undetectable HBV DNA was significantly lower in the entecavir group than in the add-on adefovir group.
Telbivudine and Elective Cesarean Section Help Prevent Mother-to-child Hepatitis B Transmission
- Details
- Category: HBV Treatment
- Published on Tuesday, 09 November 2010 12:48
- Written by Liz Highleyman
Treatment with the nucleoside analog telbivudine (Tyzeka) and birth by elective Cesarean section both reduced the likelihood of hepatitis B virus (HBV) transmission from mothers to infants during pregnancy and delivery, according to 2 separate studies presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) this week in Boston. Emergency Cesarean delivery, however, was associated with a trend toward increased transmission risk.
Danish Study Looks at Hepatitis C Sexual Transmission among HIV Positive Gay Men
- Details
- Category: HCV Sexual Transmission
- Published on Friday, 05 November 2010 12:48
- Written by Liz Highleyman
Less than 1% of HIV positive gay and bisexual men seen at a Danish hospital were found to have acute hepatitis C virus (HCV) infection, according to a study presented at the American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) this week in Boston. All those who started hepatitis C treatment within 6 months of becoming infected achieved rapid virological response, while 1 who started later experienced HCV relapse.
Which Pegylated Interferon alfa-2b Regimen Works Best for Chronic Hepatitis B?
- Details
- Category: HBV Treatment
- Published on Friday, 05 November 2010 12:48
- Written by Liz Highleyman
People with hepatitis B "e" antigen (HBeAg) positive chronic hepatitis B virus (HBV) infection respond best to a regimen of pegylated interferon alfa-2b (PegIntron) administered at 1.5 mcg/kg/week for 48 weeks, compared with a lower dose and/or shorter duration, according to a Chinese study presented last week at the American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) this week in Boston.
Boceprevir Improves Response to Interferon-based Therapy and Allows Many Patients to Reduce Duration
- Details
- Category: HCV Treatment
- Published on Tuesday, 02 November 2010 13:48
- Written by Liz Highleyman
Final results from 2 pivotal Phase 3 clinical trials presented at the American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) this week in Boston showed that adding Merck's experimental hepatitis C virus (HCV) NS3 protease inhibitor boceprevir to standard therapy increased the likelihood of sustained virological response for both previously untreated and treatment-experienced genotype 1 chronic hepatitis C patients.
More Articles...
- Tenofovir (Viread) Maintains HBV Suppression without Resistance for 4 Years
- Add-on adefovir (Hepsera) Is More Effective and Durable Than a Switch to entecavir (Baraclude) as Rescue Therapy for Epivir-resistant Patients with Chronic Hepatitis B
- Flares during HBV Treatment Do Not Predict Response, May Cause Liver Failure
- CROI 2007: HCV May Be Sexually Transmitted in HIV Negative as Well as HIV Positive Men
Web Design and Development by